[A case of recurrent ovarian cancer markedly responding to daily oral administration of low dose etoposide].
A 67-year-old woman with recurrent ovarian cancer, who had carcinomatous peritonitis and large abdominal cystic lesions, was treated by daily oral etoposide at a dose of 50 mg/day for 21 consecutive days at 2-week intervals in the outpatient department. After 15 days of administration, the serum level of CA125 decreased from 2,220U/ml to 445U/ml, and that of LDH from 2,725 WU to 906 WU. After the third course of treatment, the abdominal cystic lesions were remarkably reduced, and the performance status improved grade 1 from 3 prior to the administration. No severe side effects except for alopecia and mild myelosuppression were noted during the 3-month treatment.
Fujita
H
H
Dept. of Obstetrics and Gynecology, Kyoto Prefectural University of Medicine.
Ito
R
R
Yamamoto
T
T
Okada
H
H
D000284:Administration, Oral; D000368:Aged; D003536:Cystadenocarcinoma / Q000188:drug therapy / Q000556:secondary*; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000473:pathology* / Q000601:surgery; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000556:secondary*; D012074:Remission Induction
D005047:Etoposide